FibroBiologics is now evaluating its fibroblast platform in Hantavirus disease models, with particular emphasis on inflammatory cytokine modulation and endothelial permeability reduction. The company ...
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...
Please provide your email address to receive an email when new articles are posted on . A master cell bank has been completed for a product that will utilize fibroblasts to treat chronic wounds.
The research group of Prof. Sanjiv Luther at the Department of Immunobiology of the University of Lausanne has discovered that a fibroblast subtype is essential for coordinating certain immune cells ...
(Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases ...
HOUSTON, March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the ...
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 HOUSTON, April 30, 2026 (GLOBE NEWSWIRE)-- FibroBiologics, Inc. (Nasdaq: FBLG) ...
Keloids are raised, overgrown scars that can develop after skin injuries or surgery, often extending beyond the original wound boundaries. For many people, keloids are more than just a cosmetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results